Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00232154 · ClinicalTrials.gov registry record · Phase 2

A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To

A Phase 2 study of Sinusitis, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
72
Enrollment target
18
Study locations

NCT00232154 is a Phase 2 study of Sinusitis that has completed, run by Pfizer. The registered enrollment target is 72 participants, below the 125-participant average among 12 other Sinusitis trials with a reported enrollment target (42% lower). The trial reports 18 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00232154, a Phase 2 study of Sinusitis, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target
18
Study locations

Study Summary

To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.

Conditions Studied

Interventions

  • DRUG Zithromax™ (azithromycin) 500mg tablets
  • PROCEDURE Endoscopic Sinus Surgery
  • PROCEDURE Blood sampling for hematology
  • PROCEDURE Blood sampling for plasma chemistry profile
  • PROCEDURE Serum pregnancy test (for women of child-bearing potential)

Study Locations (18)

Alabama

  • Pfizer Investigational Site - Alabaster
  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Hoover
  • Pfizer Investigational Site - Hoover

Illinois

  • Pfizer Investigational Site - Elgin
  • Pfizer Investigational Site - Elgin
  • Pfizer Investigational Site - Maywood

Kentucky

  • Pfizer Investigational Site - Carrollton
  • Pfizer Investigational Site - La Grange
  • Pfizer Investigational Site - Louisville

Florida

  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Miami

California

  • Pfizer Investigational Site - Fresno

Georgia

  • Pfizer Investigational Site - Augusta

North Carolina

  • Pfizer Investigational Site - Durham

Pennsylvania

  • Pfizer Investigational Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2005-11
Est. Completion 2006-06
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00232154

The ClinicalTrials.gov registry entry for NCT00232154 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 12 other Sinusitis trials with a reported enrollment target (42% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sinusitis appearing as the primary indexed condition, and to 5 interventions - of which Zithromax™ (azithromycin) 500mg tablets is the first listed.

NCT00232154 reports 18 study locations spanning 8 distinct geographic areas - top geographies include Alabama, Illinois, Kentucky.

Frequently Asked Questions

What is clinical trial NCT00232154 about?

NCT00232154 is a clinical study titled "A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To". To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.

What is the current status of trial NCT00232154?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2005-11. Estimated completion is 2006-06.

What conditions does trial NCT00232154 study?

This clinical trial studies the following conditions: Sinusitis.

What interventions are being tested in trial NCT00232154?

The interventions under investigation include: Zithromax™ (azithromycin) 500mg tablets (DRUG), Endoscopic Sinus Surgery (PROCEDURE), Blood sampling for hematology (PROCEDURE), Blood sampling for plasma chemistry profile (PROCEDURE), Serum pregnancy test (for women of child-bearing potential) (PROCEDURE).

Who is sponsoring clinical trial NCT00232154?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00232154 being conducted?

This trial has 18 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sinusitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.